AU2022388751A1 - Relaxin-2 fusion protein analogs and methods of using same - Google Patents

Relaxin-2 fusion protein analogs and methods of using same Download PDF

Info

Publication number
AU2022388751A1
AU2022388751A1 AU2022388751A AU2022388751A AU2022388751A1 AU 2022388751 A1 AU2022388751 A1 AU 2022388751A1 AU 2022388751 A AU2022388751 A AU 2022388751A AU 2022388751 A AU2022388751 A AU 2022388751A AU 2022388751 A1 AU2022388751 A1 AU 2022388751A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
peptide comprises
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022388751A
Other languages
English (en)
Inventor
John Diener
Franz GRUSWITZ
Andrew KRUSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tectonic Operating Company Inc
Original Assignee
Tectonic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tectonic Operating Co Inc filed Critical Tectonic Operating Co Inc
Publication of AU2022388751A1 publication Critical patent/AU2022388751A1/en
Assigned to TECTONIC OPERATING COMPANY, INC. reassignment TECTONIC OPERATING COMPANY, INC. Amend patent request/document other than specification (104) Assignors: TECTONIC THERAPEUTIC, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022388751A 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same Pending AU2022388751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263917P 2021-11-11 2021-11-11
US63/263,917 2021-11-11
PCT/US2022/079681 WO2023086913A2 (en) 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same

Publications (1)

Publication Number Publication Date
AU2022388751A1 true AU2022388751A1 (en) 2024-05-30

Family

ID=86336636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022388751A Pending AU2022388751A1 (en) 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same

Country Status (10)

Country Link
US (2) US12509497B2 (cg-RX-API-DMAC7.html)
EP (1) EP4429694A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543455A (cg-RX-API-DMAC7.html)
KR (1) KR20240110824A (cg-RX-API-DMAC7.html)
CN (1) CN118510536A (cg-RX-API-DMAC7.html)
AU (1) AU2022388751A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237801A1 (cg-RX-API-DMAC7.html)
IL (1) IL312731A (cg-RX-API-DMAC7.html)
MX (1) MX2024005654A (cg-RX-API-DMAC7.html)
WO (1) WO2023086913A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
WO2007115414A1 (en) 2006-04-11 2007-10-18 University Of Guelph Modified h2 relaxin for tumor suppression
CA2704246A1 (en) 2007-10-30 2009-05-07 Howard Florey Institute Of Experimental Physiology And Medicine Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides
WO2010105081A1 (en) 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
US8389475B2 (en) 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
US20110245469A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
WO2012031327A1 (en) 2010-09-08 2012-03-15 Howard Florey Institute Of Experimental Physiology And Medicine Modified relaxin polypeptides
GB201110833D0 (en) 2011-06-24 2011-08-10 Bold Venture Llc Compositions
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
AU2012291972B2 (en) 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
EP2630964A1 (en) 2012-02-22 2013-08-28 Immundiagnostik AG Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
WO2013177529A1 (en) 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
US20160060322A1 (en) 2012-09-10 2016-03-03 Angion Biomedica Corp. Relaxin-like peptides and uses thereof
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US20150232526A1 (en) 2012-10-10 2015-08-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of relaxin to treat atrial fibrillation
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
JP6694381B2 (ja) 2013-09-24 2020-05-13 エラスタジェン・プロプライエタリー・リミテッドElastagen Pty Ltd タンパク質抽出方法
WO2015073727A1 (en) 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
EP3083977B1 (en) * 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Improved recombinant polypeptide production methods
CA2945838C (en) 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
WO2016144968A1 (en) 2015-03-09 2016-09-15 University Of Washington Relaxin therapy for disorders of the diaphragm
GB201516068D0 (en) 2015-09-10 2015-10-28 Biomed Ltd B V Novel therapy
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
US20190307811A1 (en) 2016-08-04 2019-10-10 Hudson Institute of Medical Research Method for treating airways disease
EP3522911B1 (en) 2016-10-07 2021-12-08 Beth Israel Deaconess Medical Center, Inc. Compositions comprising relaxin and methods of use thereof
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP4058048A1 (en) 2019-11-16 2022-09-21 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Medical composition for treating cardiac wasting and cachexia
JP2023524981A (ja) * 2020-05-08 2023-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 操作されたリラキシンおよびその使用の方法
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
WO2021247475A1 (en) 2020-06-02 2021-12-09 Trustees Of Boston University Production of soluble relaxin and relaxin analogs
CR20230015A (es) 2020-06-17 2023-02-17 Medimmune Ltd Fusiones heterodiméricas de relaxina y usos de las mismas
CN114075276A (zh) 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效松弛素2类似物
CN113577289A (zh) 2021-01-11 2021-11-02 张莉 Rxfp1/3抑制剂在制备预防或治疗青少年特发性脊柱侧凸疾病的药物中的用途
WO2023028008A2 (en) 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
EP4402474A1 (en) 2021-09-14 2024-07-24 Bellylabs OY Assay method for relaxin
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2024546877A (ja) 2021-12-15 2024-12-26 メドイミューン・リミテッド ヘテロ二量体リラキシン融合物を使用した治療
JP2025517100A (ja) 2022-05-07 2025-06-03 北京拓界生物医薬科技有限公司 リラキシン又は類似体の融合タンパク質及びその医薬的使用
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー. カーゲー 免疫抑制薬及び処置方法
EP4713001A2 (en) * 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Also Published As

Publication number Publication date
CN118510536A (zh) 2024-08-16
US20230340058A1 (en) 2023-10-26
KR20240110824A (ko) 2024-07-16
EP4429694A2 (en) 2024-09-18
JP2024543455A (ja) 2024-11-21
EP4429694A4 (en) 2025-10-01
IL312731A (en) 2024-07-01
MX2024005654A (es) 2024-09-11
US20260234213A1 (en) 2026-08-13
CA3237801A1 (en) 2023-05-19
WO2023086913A3 (en) 2023-06-22
WO2023086913A2 (en) 2023-05-19
US12509497B2 (en) 2025-12-30

Similar Documents

Publication Publication Date Title
EP3393500B1 (en) Polymer conjugates having reduced antigenicity
US12509497B2 (en) Relaxin-2 fusion protein analogs and methods of using same
CN103379915A (zh) Hsa相关组合物及使用方法
EP2536757A1 (en) Fibronectin based scaffold domain proteins that bind il-23
KR20170044115A (ko) 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
US20170239363A1 (en) Polymer conjugates having reduced antigenicity and methods of using the same
JP7465378B2 (ja) Hiv融合体を標的とするポリペプチド
US12264188B2 (en) Relaxin-2 fusion proteins
US20220119448A1 (en) Artificial recombinant protein for improving performance of active protein or polypeptide and use thereof
WO2018207023A2 (en) Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
CN116003634A (zh) Cd164融合蛋白及其应用
JP2023524981A (ja) 操作されたリラキシンおよびその使用の方法
JP2024537239A (ja) インターロイキン-10ムテイン及びその融合タンパク質
US20260085125A1 (en) Apelin receptor binding polypeptides and methods
HK40091844A (en) Dual function proteins and pharmaceutical composition comprising same
HK40086042A (en) Dual function proteins and pharmaceutical composition comprising same
Egerer et al. The Prevention of HIV Infection with Viral Entry Inhibitors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: TECTONIC OPERATING COMPANY, INC.

Free format text: FORMER NAME(S): TECTONIC THERAPEUTIC, INC.